Cemvita Factory is working on a pilot plant with Oxy to scale its biotechnology. Photo via OxyLowCarbon.com

Occidental's venture arm — Oxy Low Carbon Ventures — has announced its plans to construct and operate a one metric ton per month bio-ethylene pilot plant featuring Houston-based Cemvita Factory's technology that biomimics photosynthesis to convert carbon dioxide into feedstocks.

The new plant will scale the process, which was jointly developed between Cemvita and OLCV, and is expected sometime next year, according to a press release from Oxy.

"Today bio-ethylene is made from bio-ethanol, which is made from sugarcane, which in turn was created by photosynthesizing CO2. Our bio-synthetic process simply requires CO2, water and light to produce bio-ethylene, and that's why it saves a lot of cost and carbon emissions," says Moji Karimi, co-founder and CEO of Cemvita Factory, in the release. "This project is a great example of how Cemvita is applying industrial-strength synthetic biology to help our clients lower their carbon footprint while creating new revenue streams."

Oxy and Cemvita have been working together for a while, and in 2019, OLCV invested an undisclosed amount into the startup. The investment, according to the release, was made to jointly explore how these advances in synthetic biology can be used for sustainability efforts in the bio-manufacturing of OxyChem's products.

"This technology could provide an opportunity to offer a new, non-hydrocarbon-sourced ethylene product to the market, reducing carbon emissions, and in the future benefit our affiliate, OxyChem, which is a large producer and consumer of ethylene in its chlorovinyls business," says Robert Zeller, vice president of technology at OLCV, in a news release.

Moji Karimi founded the company with his sister and Cemvita CTO, Tara, in 2017. The idea was to biomimic photosynthesis to take CO2 and turn it into something else. The first iteration of the technology turned CO2 into sugar — the classic photosynthesis process. Karimi says the idea was to create this process for space, so that astronauts can turn the CO2 they breathe out into a calorie source.

"Nature provided the inspiration," noted Dr. Tara Karimi, co-founder and CTO of Cemvita Factory. "We took a gene from a banana and genetically engineered it into our CO2-utilizing host microorganism. We are now significantly increasing its productivity with the goal to achieve commercial metrics that we have defined alongside OLCV."

A couple weeks ago, Moji Karimi joined the Houston Innovators Podcast to discuss growth and challenges Cemvita Factory faced.

"We're defining this new category for application of synthetic biology in heavy industries for decarbonization," he shares on the show. Stream the episode below.

Moji Karimi, co-founder and CEO of Cemvita Factory, is offering energy execs an innovative way to meat their climate change pledge goals. Photo courtesy of Cemvita

Growing Houston biotech startup is capturing a new way for oil and gas to get to carbon negative

HOUSTON INNOVATORS PODCAST EPISODE 76

As more and more energy companies are focusing on reducing their carbon footprint ahead of lofty clean energy goals, Moji Karimi, CEO and co-founder of Houston-based Cemvita Factory, is doing his oil and gas clients one better. In addition to reducing carbon emissions, Cemvita provides an additional revenue stream for its clients.

Karimi founded the company with his sister and Cemvita CTO, Tara, in 2017. The idea was to biomimic photosynthesis to take CO2 and turn it into something else. The first iteration of the technology turned CO2 into sugar — the classic photosynthesis process. Karimi says the idea was to create this process for space, so that astronauts can turn the CO2 they breathe out into a calorie source.

"While we were doing that, we realized the big picture is not just the space application. If we could apply the same technology for other chemicals made in energy-intensive way, then we could actually help with climate change," Karimi says on the podcast.

Now, Cemvita has 30 different molecules its technology can produce and works with the likes of BHP, Oxy, and more energy clients to take their carbon emissions and turn it into something useful.

"It's not just for sustainability reasons — it's part of the reinvention of the company to maintain its legacy for the next few decades to come," Karimi adds.

While 2020 was a chance for Cemvita to reset, by Q4 of last year the company was in growth mode and got back to the lab. The company's teams were divided between two spots — one being an R&D team in larger office at JLABS @ TMC — and Karimi says later this year that will change. Cemvita is moving into a larger, combined space in Upper Kirby in May.

But Karimi says one of the biggest challenges Cemvita is facing is that its doing something that's never been done before. There's a huge learning curve for clients and oil and gas stakeholders.

"There weren't biotech companies working with oil and gas companies for this use case that we have now," Karimi says. "We're defining this new category for application of synthetic biology in heavy industries for decarbonization."

There are other companies in the carbon capture and neutralization fields, though they are taking slightly different approaches. Rather than being competitive, companies in this space are working together for a greater good.

"The more successful that some of these other companies are in opening up the market, that also helps us the same way we're doing for them," Karimi says. "It's an interesting and collaborative area, because at the end of the day, the outcome is good for the world."

Karimi shares more about what Cemvita's growth plans on the episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston Methodist receives $25M gift, renames department of medicine

med funding

Houston-based nonprofit The Duncan Fund has awarded a $25 million gift to Houston Methodist's department of medicine to establish new endowed fellowships, streamline complex care and bring artificial intelligence into the fold to develop more personalized treatment plans.

In turn, the health care system announced that it will rename the department the Charles W. Duncan Jr. Department of Medicine at Houston Methodist.

“We are deeply appreciative of the Duncan family’s support, which allows us to further programs at the intersection of personalized medicine and preventive health care to benefit our patients,” Dr. Eleftherios Mylonakis, chair of the department and the Charles and Anne Duncan Presidential Distinguished Chair, said in a news release.

The department of medicine is Houston Methodist's largest, and comprises 13 clinical programs, ranging from general medicine to highly specialized care, as well as research and education.

According to Houston Methodist, the latest grant from the Duncan family will:
  • Coordinate complex, multidisciplinary care by hospitalists
  • Implement programs that leverage data and AI to tailor treatments and preventive strategies
  • Establish five endowed fellowships, including a new fellowship for students known as MedTech Innovator

“Our vision is to redefine how care is delivered in our country by creating a national model for true continuity — one that follows the patient across every transition, from home to hospital and back again,” Mylonakis added in the release. “We are also advancing a deeper understanding of health span, shifting from reactive treatment to a proactive, lifelong strategy that maximizes not just how long we live but how well we live.”

The Duncan family has been a longtime supporter of Houston Methodist—and Houston organizations at large. The late Charles Duncan Jr. sat on the system's board for decades, and his son, Charles “Carlos” Duncan III, serves on the Houston Methodist Hospital Foundation Board. Additionally, the family established the Charles and Anne Duncan Scholars Program and endowed chairs in nephrology and endocrinology.

Charles Duncan Jr. is also the namesake behind Rice University's Duncan Residential College and was one of the founders of the Greater Houston Partnership. He served as Secretary of Energy during the Carter Administration.

New York Stock Exchange Texas announces location for Dallas headquarters

NYSE Texas

A location has been chosen for The New York Stock Exchange Texas, the new Dallas-based offshoot of the The New York Stock Exchange in New York.

According to a release, the NYSE Texas has leased 28,000 square-feet of space at Old Parkland, the hospital-turned office space at 3819 Maple Ave. in Oak Lawn, where it will operate as a fully electronic equities exchange headquartered in Dallas. The property is owned by Dallas billionaire Harlan Crowe, who acquired it in 2006.

The NYSE is part of the Intercontinental Exchange, Inc., a global provider of technology and data. It was previously the NYSE Chicago, which will close once the bureau in Texas debuts.

They’ve also named a president to the Texas branch: Bryan Daniel, former chairman of the Texas Workforce Commission. In his new role over the NYSE Texas, Daniel will report to President of NYSE Group Lynn Martin.

Relocating from Chicago to Texas was a response to Texas' pro-business profile, Martin says in a statement.

“As the state with the largest number of NYSE listings, representing over $3.7 trillion in market value for our community, Texas is a market leader in fostering a pro-business atmosphere,” Martin says. “We are delighted to expand our presence in the Lone Star State, which plays a key role in driving our U.S. economy forward.”'

The move comes five months after the Texas Stock Exchange — AKA TXSE — announced plans to launch in Dallas and begin trading in 2026, pending approval from the U.S. Securities and Exchange Commission. The Texas Stock Exchange is backed by financial giants such as BlackRock, Citadel Securities, and Charles Schwab.

The NYSE expects the Texas location to open in 2026, where it will operate electronically, with stocks trading across multiple venues regardless of where they are first listed, according to the release.

---

This article originally appeared on CultureMap.com.